Zydus Lifesciences Ltd (BOM:532321)
₹ 964.4 -8.55 (-0.88%) Market Cap: 970.41 Bil Enterprise Value: 965.67 Bil PE Ratio: 22.61 PB Ratio: 4.45 GF Score: 97/100

Q2 2020 Cadila Healthcare Ltd Earnings Call Transcript

Nov 13, 2019 / 12:30PM GMT
Release Date Price: ₹224.65 (-2.43%)
Operator

Ladies and gentlemen, good day, and welcome to the Q2 FY '20 Post Results Conference Call of Cadila Healthcare Limited. (Operator Instructions) Please note that this conference is being recorded.

I now hand the conference over to Mr. Ganesh Nayak, COO and Executive Director of Cadila Healthcare Limited. Thank you, and over to you, sir.

Ganesh Narayan Nayak
Cadila Healthcare Limited - COO & Executive Director

Good evening, ladies and gentlemen. It's my pleasure to take you through the performance and results of the second quarter of FY '20. We have with us Dr. Sharvil Patel, Managing Director; Mr. Nitin Parekh, CFO; Mr. Harish Sadana, Chief Strategy Officer; and Vishal Gor, Senior Vice President, Corporate Finance.

During the second quarter, on a consolidated basis, our revenues grew by 14% year-on-year to INR 33.7 billion. We posted an EBITDA of INR 6.2 billion, with a margin of 18.6%. Financials of Q2 FY '20 include a one-time charge of INR 2.68 billion in the form of impairment of levorphanol intangibles on account of an entry of a new

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot